Companies with strong catalyst profiles, manageable dilution risk, and Grade A or B BiotechSign scores. Updated daily.
BiotechSign screens biotech stocks for the most likely acquisition targets in 2026 based on pipeline quality, FDA catalyst timelines, and balance sheet strength. These are companies frequently cited as prime biotech M&A candidates: late-stage biotechs with Phase 3 readouts, low dilution risk, and proven mechanisms that large pharma acquirers actively seek. Our scoring model combines dilution analysis, catalyst grading, and public market signals to identify the least likely and most likely biotech takeover targets ahead of market consensus.
Criteria: Grade A/B · BiotechSign Score ≥ 65 · Dilution risk not HIGH or CRITICAL · Click column headers to sort